Alessandro Vinciguerra, Francesca Caspani, Marco Valentini, Anna Maria Camarda, Salvatore Provenzano, Eric W Wang, Cem Meço, Marco Ferrari, Pavol Surda, Semi Harrabi, Fernando Augusto Batista Campos, Javier Martin Broto, B Ashleigh Guadagnolo, Pierina Navarria, Ali Hosni, Nadia Hindi, Antoine Italiano, Daniel M Trifiletti, Bernd Kasper, Benjamin Verillaud, Alberto Schreiber, Paolo Castelnuovo, Piero Nicolai, Iacopo Dallan, Matias Chacon, Shirley Y Su, Juliette Thariat, Claudia Valverde, Matt Lechner, Jean Yves Blay, Maria Rosaria Fiore, Jean Anderson Eloy, Mehdi Brahmi, James N Palmer, Victor Castro Oliden, Daniela Greto, Iwona Lugowska, Angelo Paolo Dei Tos, Thibaut van Zele, Alkis J Psaltis, Paolo Giovanni Casali, Armelle Dufresne, Claudia Sangalli, Christos Georgalas, Ester Orlandi, Peter-John Wormald, Philippe Herman, Ricardo Carrau, Ehab Y Hanna, Lisa Licitra, Mario Turri-Zanoni, Paolo Battaglia
{"title":"鼻窦肉瘤的治疗：国际共识声明。","authors":"Alessandro Vinciguerra, Francesca Caspani, Marco Valentini, Anna Maria Camarda, Salvatore Provenzano, Eric W Wang, Cem Meço, Marco Ferrari, Pavol Surda, Semi Harrabi, Fernando Augusto Batista Campos, Javier Martin Broto, B Ashleigh Guadagnolo, Pierina Navarria, Ali Hosni, Nadia Hindi, Antoine Italiano, Daniel M Trifiletti, Bernd Kasper, Benjamin Verillaud, Alberto Schreiber, Paolo Castelnuovo, Piero Nicolai, Iacopo Dallan, Matias Chacon, Shirley Y Su, Juliette Thariat, Claudia Valverde, Matt Lechner, Jean Yves Blay, Maria Rosaria Fiore, Jean Anderson Eloy, Mehdi Brahmi, James N Palmer, Victor Castro Oliden, Daniela Greto, Iwona Lugowska, Angelo Paolo Dei Tos, Thibaut van Zele, Alkis J Psaltis, Paolo Giovanni Casali, Armelle Dufresne, Claudia Sangalli, Christos Georgalas, Ester Orlandi, Peter-John Wormald, Philippe Herman, Ricardo Carrau, Ehab Y Hanna, Lisa Licitra, Mario Turri-Zanoni, Paolo Battaglia","doi":"10.1002/alr.70038","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Sinonasal sarcomas are exceedingly rare entities, constituting less than 7% of head and neck sarcomas. Their complex histology needs specialized treatment, which is often based on multimodal approaches including surgery, radiation therapy, and/or chemotherapy. This manuscript aims to gather expert opinions to establish common management principles for sinonasal sarcomas.</p><p><strong>Methods: </strong>This international consensus followed a modified Delphi method in seven steps, including statements definition by the core group, expert panel recruitment, and a two-round survey. Sixty-two statements on sinonasal sarcoma management were developed. Experts from multiple continents participated, and results were anonymized and analyzed between March and May 2025.</p><p><strong>Results: </strong>A total of 44 invited experts were recruited, 43.2% otorhinolaryngologists/head and neck surgeons, 31.8% medical oncologists, and 25% radiation oncologists. Participants varied in age and experience, representing Europe (70.5%), North America (18.2%), South America (6.8%), and Asia (4.5%). Among all histologies, biphenotypic sarcoma, chondrosarcoma, leiomyosarcoma, and myofibrosarcoma are principally treated with an upfront surgical management, differently from Ewing sarcoma and rhabdomyosarcoma in which chemotherapy, eventually associated with radiotherapy, is often chosen. In the remaining histologies (angiosarcoma, liposarcoma, malignant peripheral nerve sheath tumor [MPNST], osteosarcoma, and synovial sarcoma), a precise multimodal treatment is less standardized and needs to be discussed on a case-by-case basis.</p><p><strong>Conclusion: </strong>Sinonasal sarcomas require a histology-driven approach to determine upfront treatment, whether surgical, medical, or multimodal. Despite this structured strategy, prognosis remains highly variable across subtypes. Multidisciplinary evaluation and individualized management in referral centers are crucial to address the biological diversity and anatomical complexity of these rare malignancies.</p>","PeriodicalId":13716,"journal":{"name":"International Forum of Allergy & Rhinology","volume":" ","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Sinonasal Sarcomas Management: An International Consensus Statement.\",\"authors\":\"Alessandro Vinciguerra, Francesca Caspani, Marco Valentini, Anna Maria Camarda, Salvatore Provenzano, Eric W Wang, Cem Meço, Marco Ferrari, Pavol Surda, Semi Harrabi, Fernando Augusto Batista Campos, Javier Martin Broto, B Ashleigh Guadagnolo, Pierina Navarria, Ali Hosni, Nadia Hindi, Antoine Italiano, Daniel M Trifiletti, Bernd Kasper, Benjamin Verillaud, Alberto Schreiber, Paolo Castelnuovo, Piero Nicolai, Iacopo Dallan, Matias Chacon, Shirley Y Su, Juliette Thariat, Claudia Valverde, Matt Lechner, Jean Yves Blay, Maria Rosaria Fiore, Jean Anderson Eloy, Mehdi Brahmi, James N Palmer, Victor Castro Oliden, Daniela Greto, Iwona Lugowska, Angelo Paolo Dei Tos, Thibaut van Zele, Alkis J Psaltis, Paolo Giovanni Casali, Armelle Dufresne, Claudia Sangalli, Christos Georgalas, Ester Orlandi, Peter-John Wormald, Philippe Herman, Ricardo Carrau, Ehab Y Hanna, Lisa Licitra, Mario Turri-Zanoni, Paolo Battaglia\",\"doi\":\"10.1002/alr.70038\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Sinonasal sarcomas are exceedingly rare entities, constituting less than 7% of head and neck sarcomas. Their complex histology needs specialized treatment, which is often based on multimodal approaches including surgery, radiation therapy, and/or chemotherapy. This manuscript aims to gather expert opinions to establish common management principles for sinonasal sarcomas.</p><p><strong>Methods: </strong>This international consensus followed a modified Delphi method in seven steps, including statements definition by the core group, expert panel recruitment, and a two-round survey. Sixty-two statements on sinonasal sarcoma management were developed. Experts from multiple continents participated, and results were anonymized and analyzed between March and May 2025.</p><p><strong>Results: </strong>A total of 44 invited experts were recruited, 43.2% otorhinolaryngologists/head and neck surgeons, 31.8% medical oncologists, and 25% radiation oncologists. Participants varied in age and experience, representing Europe (70.5%), North America (18.2%), South America (6.8%), and Asia (4.5%). Among all histologies, biphenotypic sarcoma, chondrosarcoma, leiomyosarcoma, and myofibrosarcoma are principally treated with an upfront surgical management, differently from Ewing sarcoma and rhabdomyosarcoma in which chemotherapy, eventually associated with radiotherapy, is often chosen. In the remaining histologies (angiosarcoma, liposarcoma, malignant peripheral nerve sheath tumor [MPNST], osteosarcoma, and synovial sarcoma), a precise multimodal treatment is less standardized and needs to be discussed on a case-by-case basis.</p><p><strong>Conclusion: </strong>Sinonasal sarcomas require a histology-driven approach to determine upfront treatment, whether surgical, medical, or multimodal. Despite this structured strategy, prognosis remains highly variable across subtypes. Multidisciplinary evaluation and individualized management in referral centers are crucial to address the biological diversity and anatomical complexity of these rare malignancies.</p>\",\"PeriodicalId\":13716,\"journal\":{\"name\":\"International Forum of Allergy & Rhinology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2025-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Forum of Allergy & Rhinology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/alr.70038\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OTORHINOLARYNGOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Forum of Allergy & Rhinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/alr.70038","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
Sinonasal Sarcomas Management: An International Consensus Statement.
Introduction: Sinonasal sarcomas are exceedingly rare entities, constituting less than 7% of head and neck sarcomas. Their complex histology needs specialized treatment, which is often based on multimodal approaches including surgery, radiation therapy, and/or chemotherapy. This manuscript aims to gather expert opinions to establish common management principles for sinonasal sarcomas.
Methods: This international consensus followed a modified Delphi method in seven steps, including statements definition by the core group, expert panel recruitment, and a two-round survey. Sixty-two statements on sinonasal sarcoma management were developed. Experts from multiple continents participated, and results were anonymized and analyzed between March and May 2025.
Results: A total of 44 invited experts were recruited, 43.2% otorhinolaryngologists/head and neck surgeons, 31.8% medical oncologists, and 25% radiation oncologists. Participants varied in age and experience, representing Europe (70.5%), North America (18.2%), South America (6.8%), and Asia (4.5%). Among all histologies, biphenotypic sarcoma, chondrosarcoma, leiomyosarcoma, and myofibrosarcoma are principally treated with an upfront surgical management, differently from Ewing sarcoma and rhabdomyosarcoma in which chemotherapy, eventually associated with radiotherapy, is often chosen. In the remaining histologies (angiosarcoma, liposarcoma, malignant peripheral nerve sheath tumor [MPNST], osteosarcoma, and synovial sarcoma), a precise multimodal treatment is less standardized and needs to be discussed on a case-by-case basis.
Conclusion: Sinonasal sarcomas require a histology-driven approach to determine upfront treatment, whether surgical, medical, or multimodal. Despite this structured strategy, prognosis remains highly variable across subtypes. Multidisciplinary evaluation and individualized management in referral centers are crucial to address the biological diversity and anatomical complexity of these rare malignancies.
期刊介绍：
International Forum of Allergy & Rhinologyis a peer-reviewed scientific journal, and the Official Journal of the American Rhinologic Society and the American Academy of Otolaryngic Allergy.
International Forum of Allergy Rhinology provides a forum for clinical researchers, basic scientists, clinicians, and others to publish original research and explore controversies in the medical and surgical treatment of patients with otolaryngic allergy, rhinologic, and skull base conditions. The application of current research to the management of otolaryngic allergy, rhinologic, and skull base diseases and the need for further investigation will be highlighted.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
